Activating Rather Than Inhibiting –
Caladrix Therapeutic Paradigm
Most drugs on the market today work by inhibiting their target: enzymes, receptors, ion channels, or transporters. The goal is to reduce or block excessive activity that contributes to disease. But what if the underlying problem isn’t overactivity – but insufficient or impaired function?
At Caladrix, we take a fundamentally different approach. Our drug candidates are designed to activate proteins – specifically ABC transporters – to restore the body’s natural protective mechanisms against neurodegeneration.
Why Activation Matters
ABC (ATP-binding cassette) transporters are key players in brain health. They help clear toxic peptides such as amyloid-beta, regulate inflammation, and protect cells from oxidative stress. Their function tends to decline with age – just when the brain needs them most.